Cann Global has teamed up with Western Sydney University’s NICM Health Research Institute to evaluate the efficacy of a unique strain of medicinal cannabis to slow the progression of Multiple Sclerosis (MS).

The proposed human clinical trials follow successful research undertaken for Cann Global at the Technion in Israel headed by Dr Dedi Meiri which identified a chemovar in a unique cannabis strain that both in vitro and in vivo (in mice trials) stopped the progression of MS, and in some cases significantly reversed the damage it caused.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Elementum integer enim neque volutpat ac tincidunt vitae semper quis. Eu lobortis elementum nibh tellus molestie nunc. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Magnis dis parturient montes nascetur ridiculus. Dui id ornare arcu odio ut sem. Nisl nunc mi ipsum faucibus vitae.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...

Join the Conversation

1 Comment

  1. I would love to be involved if I’m suitable for your trial. Is there an email address I can send you my details to?
    Many thanks
    (Living with remitting relapsing MS)